Xenon Pharmaceuticals (XENE) news
Recent news
Xenon Pharmaceuticals 2Q loss/share $1.11, est. loss/share $1.13
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) reported a second-quarter 2026 net loss of $84.7 million, or $1.07 per share, compared to net loss of $57.9 million , or $0.75 per share, in the same period in 2025. The results were slightly better than the estimated loss of $1.13 per share, with the…
AInvest Wire · Aug 6, 2026Xenon Pharmaceuticals - anticipates sufficient cash to fund operations into 2029
AInvest Wire · Aug 6, 2026Xenon Pharmaceuticals 2Q operating loss $123.2M, estimated loss $112M
AInvest Wire · Aug 6, 2026Xenon Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4)
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) has announced equity inducement grants to new employees in compliance with Nasdaq Listing Rule 5635(c)(4). On May 28, 2026, the company granted 32,750 share options and 19,200 restricted share units (RSUs) to 10 new non-officer employees. These grants were…
AInvest Wire · Jul 31, 2026ImportantXenon Pharmaceuticals pricing of upsized $650.0M offering
AInvest Wire · Mar 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.